Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTHEM, INC.

(ANTM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Blue Health Insurers Drop Revenue Rule That Limited Competition

05/03/2021 | 01:33pm EDT

By Anna Wilde Mathews

The Blue Cross Blue Shield Association said it dropped a rule that limited competition among its member insurers, moving to implement a key aspect of an antitrust settlement the companies reached last year with customers.

The settlement hasn't won final approval from the federal judge presiding over the litigation, so it isn't being fully implemented. But last Tuesday the group of insurers formally lifted a cap on the share of the members' revenue that could come from business not under a Blue Cross Blue Shield brand, one of the moves it had promised under the settlement.

Previously, the rule was that two-thirds of a Blue licensee's national net revenue from health plans and related services must stem from Blue-branded business.

The Blue Cross Blue Shield Association includes 35 insurers, each of which typically hold exclusive rights to the Blue Cross and Blue Shield brands within a certain territory, a setup that would remain intact under the antitrust settlement.

However, lifting the revenue cap could allow the Blue insurers to compete more against one another by expanding their non-Blue businesses, experts said. Dropping the limit "certainly should increase competition, " said Tim Greaney, a professor at the University of California Hastings College of the Law, though he said it isn't clear how quickly it would have an effect.

In a statement, the Blue Cross Blue Shield Association said its move was consistent with the settlement. "Blue Cross and Blue Shield companies will remain focused on the goal we have had for over 90 years -- improving access to quality healthcare for all Americans -- as the settlement continues through the Court approval process and is implemented according to terms of the Agreement," the group said.

Anthem Inc. and Health Care Service Corp. are among the largest Blue insurers. Together, all of the Blue companies cover more than 100 million Americans.

David Boies, a lead attorney for the Blue customer antitrust plaintiffs, said elimination of the restriction "will substantially increase competition in health insurance markets."

The antitrust claims were first brought in 2012 as a proposed class action on behalf of employers and individual policyholders with Blue coverage. The suit alleged that the insurers illegally conspired to divvy up markets and avoid competing against one another, driving up customers' prices.

The settlement has won preliminary approval from U.S. District Judge R. David Proctor, in Birmingham, Ala., who wrote that the deal's "structural relief is historic and substantial." The settlement requires the insurers to pay about $2.7 billion, largely to customers, and take steps that include dropping the national revenue cap.

The revenue cap was one impediment to Anthem's $48 billion deal to buy Cigna Corp., which ended up foundering largely over its own antitrust issues. That deal could have added substantially to Anthem's non-Blue revenue.

Still, the settlement wouldn't unwind the licensing structure that allows the Blue insurers to hold exclusive rights to their brands in certain geographies.

The Blue insurers are still facing a parallel antitrust suit filed on behalf of healthcare providers, which alleges that the insurers illegally pushed down the payments providers receive for medical services. Both suits, consolidated in the Alabama federal court, targeted the association and all the insurers to which it licenses Blue brands.

One reason for the insurers to take action on the revenue rule might be to improve their position in the healthcare providers' ongoing suit, by removing one practice that could be viewed as anticompetitive, Mr. Greaney said.

In response to a question about why the Blue association moved now to get rid of the revenue rule, a spokeswoman said its board made the decision "based on the terms of the settlement. It's one step in a series that we will take to fulfill our commitments under the settlement agreement."

Write to Anna Wilde Mathews at anna.mathews@wsj.com

(END) Dow Jones Newswires

05-03-21 1533ET

Stocks mentioned in the article
ChangeLast1st jan.
ANTHEM, INC. -0.38% 393.93 Delayed Quote.22.69%
CIGNA CORPORATION -0.18% 263.52 Delayed Quote.26.81%
DJ INDUSTRIAL 1.06% 34382.13 Delayed Quote.9.74%
All news about ANTHEM, INC.
05/07INSIDER TRENDS : 90-Days of Insider Buying at Anthem Interrupted with Share Disp..
MT
05/05ANTHEMá : UBS Adjusts Anthem's Price Target to $432 From $361; Buy Rating Kept
MT
05/03Health Care Up As Earnings Worries Fade -- Health Care Roundup
DJ
05/03Blue Health Insurers Drop Revenue Rule That Limited Competition
DJ
05/03STREET COLOR : Anthem Wins Appeal vs Cigna Over $1.85 Bln Deal Break-Up Fee
MT
05/03ANTHEMá : Mizuho Securities Adjusts Anthem's Price Target to $380 From $320, Mai..
MT
05/03ANTHEMá : Disconnect between increased stress and lower diagnoses rates raises c..
BU
04/29ANTHEM, INC.á : Completes Acquisition of myNEXUS Home Health Benefits Manager
BU
04/27ANTHEMá : Announces Appearance at Upcoming Conference
BU
04/22ANTHEMá : Stephens Adjusts Anthem's Price Target to $430 from $395, Keeps Overwe..
MT
More news
Financials (USD)
Sales 2021 135 B - -
Net income 2021 5 966 M - -
Net Debt 2021 14 306 M - -
P/E ratio 2021 16,3x
Yield 2021 1,07%
Capitalization 96 450 M 96 450 M -
EV / Sales 2021 0,82x
EV / Sales 2022 0,74x
Nbr of Employees 83 400
Free-Float 99,4%
Chart ANTHEM, INC.
Duration : Period :
Anthem, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTHEM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 419,18 $
Last Close Price 393,93 $
Spread / Highest target 21,6%
Spread / Average Target 6,41%
Spread / Lowest Target -15,0%
EPS Revisions
Managers and Directors
NameTitle
Gail Koziara Boudreaux President, Chief Executive Officer & Director
John Edward Gallina Chief Financial Officer & Executive Vice President
Elizabeth E. Tallett Independent Chairman
Gloria M. McCarthy Chief Administrative Officer & Executive VP
Ramiro G. Peru Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTHEM, INC.22.69%96 822
UNITEDHEALTH GROUP16.86%385 559
CIGNA CORPORATION26.81%90 590
HUMANA INC.10.35%58 824
CENTENE CORPORATION15.28%39 853
MOLINA HEALTHCARE, INC.24.62%15 478